ArticleCell death & disease2026

CRISPR/Cas9 screen identifies DCAF4 as a novel protector of hepatocellular carcinoma against brachytherapy via stress granule-dependent NRF2 activation.

Tian Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.